New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 medications semaglutide or liraglutide were less likely to ...

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

Have you finally decided to explore treatment plans for weight loss or erectile dysfunction? Are you finding that ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

The discovery of a gut-to-brain regulation pathway in flies calls for additional consideration on how certain medications, especially GLP-1 agonists, can be used to treat obesity and diabetes in ...

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...